These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33652403)

  • 41. Health technology assessment: research trends and future priorities in Europe.
    Nielsen CP; Funch TM; Kristensen FB
    J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Information technology law and health systems in the European Union.
    Mossialos E; Thomson S; Ter Linden A
    Int J Technol Assess Health Care; 2004; 20(4):498-508. PubMed ID: 15609802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
    Lipska I; McAuslane N; Leufkens H; Hövels A
    Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hard choices: Reflections from the tomb of the unknown patient.
    McCabe C; Round J
    Healthc Manage Forum; 2019 Nov; 32(6):288-292. PubMed ID: 31505957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies.
    Tarricone R; Amatucci F; Armeni P; Banks H; Borsoi L; Callea G; Ciani O; Costa F; Federici C; Torbica A; Marletta M
    Health Policy; 2021 May; 125(5):602-608. PubMed ID: 33820679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
    Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
    BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health technology assessment in Denmark.
    Jørgensen T; Hvenegaard A; Kristensen FB
    Int J Technol Assess Health Care; 2000; 16(2):347-81. PubMed ID: 10932413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health technology assessment in Europe. Improving clarity and performance.
    Cookson R; Maynard A
    Int J Technol Assess Health Care; 2000; 16(2):639-50. PubMed ID: 10932428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expanding Health Technology Assessments to Include Effects on the Environment.
    Marsh K; Ganz ML; Hsu J; Strandberg-Larsen M; Gonzalez RP; Lund N
    Value Health; 2016; 19(2):249-54. PubMed ID: 27021760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thai health technology assessment guideline development.
    Teerawattananon Y; Chaikledkaew U
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S11-5. PubMed ID: 19253483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. History of health technology assessment in Belgium.
    Cleemput I; Van Wilder P
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():82-7. PubMed ID: 19500438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HTA and its legal issues: a framework for identifying legal issues in health technology assessment.
    Widrig D; Tag B
    Int J Technol Assess Health Care; 2014 Dec; 30(6):587-94. PubMed ID: 25816824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe.
    Löblová O
    Health Econ Policy Law; 2016 Jul; 11(3):253-73. PubMed ID: 26670267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health technology assessment.
    Papatheofanis FJ
    Q J Nucl Med; 2000 Jun; 44(2):105-11. PubMed ID: 10967621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.